Hepatocellular Carcinoma Study Comparing Vaccinia Virus Based Immunotherapy Plus Sorafenib vs Sorafenib Alone
Status:
Completed
Trial end date:
2020-07-01
Target enrollment:
Participant gender:
Summary
This is a randomized Phase 3 study to determine whether treatment with vaccinia virus based
immunotherapy (Pexa-Vec) followed by sorafenib increases survival compared to treatment with
sorafenib in patients with advanced hepatocellular carcinoma who have not received prior
systemic therapy.